Jim Simons
ABVC icon

Jim Simons’s ABVC BioPharma ABVC Stock Holding History

Jim Simons’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95,100
Closed -$92.3K – 3146
2026
Q1 		$92.3K Sell
95,100
-19,163
-17% -$31.7K ﹤0.01% 3042
2025
Q4 		$243K Buy
114,263
+3,763
+3% +$10.1K ﹤0.01% 2838
2025
Q3 		$336K Buy
110,500
+68,794
+165% +$211K ﹤0.01% 2958
2025
Q2 		$92.8K Buy
+41,706
New +$56.8K ﹤0.01% 3311
2024
Q1 		– Sell
-36,100
Closed -$42K – 3660
2023
Q4 		$42K Buy
+36,100
New +$42.6K ﹤0.01% 3479

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jim Simons's ABVC Position: Q2 2026 in Review

Jim Simons sold out of ABVC BioPharma (ABVC) in Q2 2026, closing a stake of 95,100 shares — an estimated $92.3K sold.

Jim Simons first reported a position in ABVC in Q4 2023 and held it in 5 quarters. The position peaked at $336K in Q3 2025. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Jim Simons reported no remaining ABVC BioPharma position as of Q2 2026 after selling out during the quarter.
  • Jim Simons sold 95,100 ABVC BioPharma shares in Q2 2026, an estimated $92.3K.
  • Jim Simons first reported a position in ABVC BioPharma in Q4 2023 and held it in 5 quarters.
  • Jim Simons's ABVC BioPharma position peaked at $336K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.